Posted by Michael Wonder on 03 Jul 2018
NICE says Tookad too expensive for prostate cancer
3 July 2018 - The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
In preliminary guidelines, the Institute’s appraisal committee said the drug is not cost effective for untreated unilateral, low-risk prostate cancer in adults when compared with active monitoring, surgery or radiotherapy.
“Clinical trial evidence shows padeliporfin can slow disease progression, but its long-term effectiveness is unclear and there is no evidence to show how effective it is when compared with surgery or radiotherapy,” NICE said.
